Clarithromycin

As a commonly used macrolide antibiotic in clinical practice, clarithromycin exerts its antibacterial activity by binding to the 50S subunit of bacterial ribosomes and inhibiting protein synthesis, and has a strong inhibitory effect on Gram-positive bacteria, some Gram-negative bacteria, mycoplasma and chlamydia. It is mainly used clinically for the treatment of respiratory tract infections, skin and soft tissue infections, and combined eradication therapy for *Helicobacter pylori*, with its applicable population covering adults and children over 6 months old, and it is one of the core drugs in the regimens for community-acquired infections and *Helicobacter pylori* eradication in the gastroenterology department.

The domestic market size of clarithromycin API is approximately RMB 1.2 billion, with a compound annual growth rate of 4.2% in the past three years, and the demand side is stably supported by the expansion of the primary medical market and the high *Helicobacter pylori* infection rate. In terms of the competitive landscape, there are a total of 17 domestic manufacturers, the combined market share of the top 3 enterprises exceeds 65%, and the export proportion of products from enterprises that have obtained FDA certification reaches 38%. With the implementation of national centralized procurement in recent years, the quality compliance of APIs has become the core assessment indicator for downstream preparation enterprises when selecting suppliers.

CATO can provide a full set of impurity reference standards for clarithromycin API. All products meet the registration requirements of multiple regulations such as the Chinese Pharmacopoeia and FDA, with sufficient in-stock inventory available for same-day delivery, which fully meets the demand for impurity reference standards in the stages of API R&D, quality research and registration declaration, and helps enterprises shorten the R&D cycle and reduce compliance risks.